Recombinant Envafolimab Biosimilar anticorps

N° du produit ABIN7795134

L’anticorps anti-Envafolimab Biosimilar Monoclonal Humanized est utilisé pour la détection de Envafolimab Biosimilar dans des échantillons de Humain. Il a été validé pour FACS et in vivo.

Aperçu rapide pour Recombinant Envafolimab Biosimilar anticorps (ABIN7795134)

Antigène: Envafolimab Biosimilar

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Humanized

Clonalité: Monoclonal

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit

Expression System: Mammalian cells

Fonction: Envafolimab Biosimilar, PD-L1 Monoclonal Antibody

Attributs du produit: What is envafolimab biosimilar research grade? Envafolimab is a humanized nanobody (VHH-hIgG1 Fc fusion protein) directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Envafolimab biosimilar uses the same protein sequences as the therapeutic antibody envafolimab. PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Envafolimab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body's adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human PD-L1

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détail du antigène

Antigène: Envafolimab Biosimilar

Classe de substances: Biosimilar